Atosiban acetate propter anti premature nativitatis
Product Detail
| Nomen | Atosiban |
| Cas numerum | 90779-69-4 |
| MOLECULA | C43h67n11o12s2 |
| Pondus | 994,19 |
| Einecs numerum | 806-815-5 |
| PRAETERITUS | 1469,0 ± 65.0 ° (Praedicta) |
| Densitas | 1.254 ± 0.06 G / CM3 (praedicta) |
| Conditions repono | -20 ° C |
| Solubility | H2O: ≤100 mg / ml |
Descriptio
Atosiban acetate est disulfide-bonded cyclic polypeptide constans ex IX amino acida. It is a modified oxytocin molecule at positions 1, 2, 4 and 8. The N-terminus of the peptide is 3-mercaptopropionic acid (thiol and The sulfhydryl group of [Cys]6 forms a disulfide bond), the C-terminal is in the form of an amide, the second amino acid at the N-terminal is an ethylated modified [D-Tyr (et)] II et Atosiban acetate adhibetur in medicamina aceto quod est in forma acidum sal, vulgo ut atosiban acetate.
Applicatio
Atosiban est oxytocin et Vasopressin V1a combined receptor Anagonist, in Oxytocin receptor est structuram similes Vasopressin V1a receptor. Cum oxytocin receptor clausus, oxytocin potest agere per V1a receptor, ita necesse est ut angustos super duo receptor meatus simul et unum contrahit unum receptor potest efficaciter inhibere inhibere contractio. Hoc quoque est unum ex principalis causas cur β-receptor agonists, calcium alveo blockers et prostaglandin synthase inhibitors non efficaciter inhibere vteri contractionem.
Ecfectio
Athosiban est combined receptor Anagonist of Oxytocin et Vasopressin V1a, eius eget structuram est similis duo, et habet altum affinitatem ad receptores, et certat cum oxytocin et v1a receptores, ita et reducing vterine contracturas et vasopressin et reducing vterine contracturas.
